On Monday, Heron Therapeutics Inc (NASDAQ: HRTX) opened higher 5.14% from the last session, before settling in for the closing price of $1.75. Price fluctuations for HRTX have ranged from $0.50 to $3.93 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 17.85% over the last five years. Company’s average yearly earnings per share was noted 84.30% at the time writing. With a float of $144.08 million, this company’s outstanding shares have now reached $150.29 million.
The firm has a total of 126 workers. Let’s measure their productivity. In terms of profitability, gross margin is 65.49%, operating margin of -34.02%, and the pretax margin is -35.29%.
Heron Therapeutics Inc (HRTX) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Heron Therapeutics Inc is 5.00%, while institutional ownership is 81.29%. The most recent insider transaction that took place on Nov 17 ’23, was worth 27,250. In this transaction EVP, Chief Development Officer of this company bought 25,000 shares at a rate of $1.09, taking the stock ownership to the 79,000 shares. Before that another transaction happened on Nov 16 ’23, when Company’s EVP, Chief Development Officer bought 50,000 for $0.94, making the entire transaction worth $46,995. This insider now owns 54,000 shares in total.
Heron Therapeutics Inc (HRTX) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 84.30% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 47.50% during the next five years compared to 20.01% growth over the previous five years of trading.
Heron Therapeutics Inc (NASDAQ: HRTX) Trading Performance Indicators
Check out the current performance indicators for Heron Therapeutics Inc (HRTX). In the past quarter, the stock posted a quick ratio of 1.85. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.02.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.33, a number that is poised to hit -0.04 in the next quarter and is forecasted to reach -0.03 in one year’s time.
Technical Analysis of Heron Therapeutics Inc (HRTX)
Analysing the last 5-days average volume posted by the [Heron Therapeutics Inc, HRTX], we can find that recorded value of 1.39 million was lower than the volume posted last year of 2.38 million. As of the previous 9 days, the stock’s Stochastic %D was 40.85%. Additionally, its Average True Range was 0.11.
During the past 100 days, Heron Therapeutics Inc’s (HRTX) raw stochastic average was set at 17.83%, which indicates a significant decrease from 47.46% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 49.57% in the past 14 days, which was lower than the 83.81% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.8664, while its 200-day Moving Average is $2.5810. Now, the first resistance to watch is $1.9100. This is followed by the second major resistance level at $1.9800. The third major resistance level sits at $2.0650. If the price goes on to break the first support level at $1.7550, it is likely to go to the next support level at $1.6700. Now, if the price goes above the second support level, the third support stands at $1.6000.
Heron Therapeutics Inc (NASDAQ: HRTX) Key Stats
There are currently 151,668K shares outstanding in the company with a market cap of 275.92 million. Presently, the company’s annual sales total 127,040 K according to its annual income of -110,560 K. Last quarter, the company’s sales amounted to 36,020 K and its income totaled -9,240 K.
